Bayer vs. Teva: Rivaroxaban Patent Dispute Ends in Stipulated Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Bayer AG v. Teva Pharmaceutical Industries, Ltd. |
| Case Number | 1:21-cv-01001 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Jul 2021 – Jan 2026 4 years 6 months |
| Outcome | Stipulated Dismissal |
| Patents at Issue | |
| Accused Products | Teva’s generic 2.5 mg rivaroxaban tablets |
Case Overview
The Parties
⚖️ Plaintiff
Global life sciences company with a substantial pharmaceutical portfolio, including XARELTO® (rivaroxaban).
🛡️ Defendant
One of the world’s largest generic drug manufacturers, routinely challenging branded pharmaceutical patents through ANDA filings.
The Patent at Issue
This case involved U.S. Patent No. US10828310B2, covering formulation or method claims related to 2.5 mg rivaroxaban tablets:
- • US10828310B2 — Formulation/method claims for 2.5 mg rivaroxaban tablets
Developing a similar pharmaceutical product?
Check if your generic drug product might infringe this or related patents.
The Verdict & Legal Analysis
Outcome
The case concluded through a **negotiated stipulated dismissal** rather than a judicial ruling on the merits. The key terms: Bayer’s claims against Teva were dismissed **with prejudice**, while Teva’s counterclaims were dismissed **without prejudice**. Each party bore its own costs and attorneys’ fees. No damages award or injunctive relief was issued, indicating a confidential commercial resolution.
Key Legal Issues: Asymmetric Dismissal
The asymmetric dismissal structure is the most analytically significant element. Bayer’s decision to accept a with-prejudice dismissal of its infringement claims effectively forecloses re-litigation of the same claims against Teva on this patent, suggesting a substantial negotiated commercial resolution. Teva’s counterclaims being dismissed **without prejudice** means they retain the right to reassert these claims in future proceedings, indicating they may have obtained commercial accommodation (e.g., an authorized generic agreement or negotiated market entry date) while preserving defensive optionality.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand ANDA litigation.
Power Your Patent Strategy with PatSnap Eureka IP
From novelty searches to patent drafting, PatSnap Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulations. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related rivaroxaban patents in this technology space
- See which pharma companies are most active in Factor Xa inhibitors
- Understand ANDA litigation and settlement patterns
🔍 Check My Drug Product’s Risk
Run a comprehensive FTO analysis for your generic drug or pharmaceutical formulation.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report for pharma IP
High Risk Area
Rivaroxaban 2.5 mg tablet formulations
Complex Patent Landscape
For Factor Xa inhibitors
ANDA Strategy Insights
From asymmetric dismissal terms
✅ Key Takeaways
For Patent Attorneys & Litigators
Asymmetric dismissal terms (with/without prejudice) signal the underlying commercial deal structure even when financial terms remain confidential.
Search related case law →Delaware remains the premier venue for pharmaceutical ANDA litigation; specialized local counsel pairing is a strategic necessity.
Explore precedents →For IP Professionals & R&D Leaders
Monitor Bayer’s rivaroxaban continuation patent portfolio for additional enforcement actions targeting generic entrants across dosage strengths.
Start FTO analysis for my product →Conduct updated FTO analyses against US10828310B2 and related Bayer/Janssen patents before advancing rivaroxaban formulation development.
Try AI patent drafting →Ready to Strengthen Your Pharmaceutical Patent Strategy?
Join thousands of IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes in the pharma sector.